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Background: In recent years the generation of antibodies by recombinant methods, such as phage display
technology, has increased the speed by which antibodies can be obtained. However, in some cases when
recombinant antibodies have to be validated, expression in E. coli can be problematic. This primarily occurs when
codon usage or protein folding of specific antibody fragments is incompatible with the E. coli translation and
folding machinery, for instance when recombinant antibody formats that include the Fc-region are needed. In such
cases other expression systems can be used, including the protozoan parasite Leishmania tarentolae (L. tarentolae).
This novel host for recombinant protein expression has recently shown promising properties for the expression of
single-chain antibody fragments. We have utilised the L. tarentolae T7-TR system to achieve expression and
secretion of two scFvs fused to the Fc-region of rabbit immunoglobulin G (IgG).
Results: Based on the commercial vector pLEXSY_IE-blecherry4 (Jena Bioscience; Cat. No. EGE-255), we generated a
vector containing the Fragment Crystallisable (Fc) region of rabbit IgG allowing insertions of single chain antibody
fragments (scFvs) in frame via Ncol/Notl cloning (pMJ_LEXSY-rFc). For the expression of rabbit Fc-fusion scFvs
(scFv-rFc) we cloned two scFvs binding to human vimentin (LOB7 scFv) and murine laminin (A10 scFv) respectively,
into the modified vector. The LOB7-rFc and A10-rFc fusions expressed at levels up to 2.95 mg/L in L. tarentolae
T7-TR. Both scFv-rFcs were purified from the culture supernatants using protein A affinity chromatography.
Additionally, we expressed three different scFvs without the rFc regions using a similar expression cassette,
obtaining yields up to 1.00 mg/L.
Conclusions: To our knowledge, this is the first time that antibody fragments with intact Fc-region of immunoglobulin
have been produced in L. tarentolae. Using the plasmid pMJ_LEXSY-rFc, L. tarentolae T7-TR can be applied as an
efficient tool for expression of rFc fusion antibody fragments, allowing easy purification from the growth medium.
This system provides an alternative in cases where antibody constructs express poorly in standard prokaryotic
systems. Furthermore, in cases where bivalent Fc-fused antibody constructs are needed, using L. tarentolae for
expression provides an efficient alternative to mammalian expression.
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Antibodies are applied in both basic research and diag-
nostics, and represent an increasingly important class of
therapeutics. Monoclonal antibodies is the largest and
fastest growing class of protein pharmaceuticals [1]. In
the discovery and development of these antibodies, anti-
body fragments such as the antigen binding fragment
(Fab), the single-chain variable fragment (scFv), and the
single variable domains (VH and VL, collectively sdAb)
are often employed [2]. The present recombinant anti-
body discovery platforms, such as ribosome and phage
display [3], enable easy screening and selection of anti-
body fragments against virtually any antigen [4]. Based
on the initial screening or selection, a number of candi-
date antibodies are obtained [3]. Often, these recombi-
nant antibody candidates can be expressed in E. coli.
However, although the field of recombinant protein ex-
pression in E. coli is developed and expanded [5,6], the
codon usage and folding dynamics of some recombinant
antibody clones are incompatible with the bacterial ex-
pression machinery [7,8]. In addition, for further evalu-
ation of an antibody fragment it can be necessary to test
additional formats, including the Fc-fusion format; such
formats are inherently unsuitable for (but not outright
incompatible with) prokaryotic expression [7,9].
Modifying a Fab, scFv, or sdAb by fusing them to the
Fc-region will produce a bivalent antibody format similar
to the canonical antibody [10,11]. The bivalent format
increases the apparent affinity due to avidity, provided
that multiple epitopes are available.
A further benefit of the Fc-fusion that potentially can be
imparted to some antibody fragments is a decrease in their
propensity to aggregate [1,12]. At the same time the mo-
lecular sizes of the Fc-fused antibodies increase from ap-
proximately 12, 25, or 50 kDa (sdAb, scFv, and Fab
respectively) to approximately 75, 100, or 150 kDa. An in-
crease of molecular size in this range will greatly increase
the serum half-life of a recombinant antibody, by putting
it beyond the cut-off for renal clearance. For example na-
tive IgG1 of approximately 150 kDa has a serum half-life
of around 21 days, whereas the serum half-lives of sdAb
and scFv are in the area of 0.05 and 0.1 days respectively
[13]. The longer serum half-life of native IgG and of some
of the larger recombinant formats is only partly attributed
to their molecular size. The longer serum half-life is
furthermore a consequence of the interactions of the Fc-
region with the neonatal Fc receptor (FcRn). The inter-
action with FcRn salvages the antibodies from endosomes
and returns them to circulation, rather than letting them
enter the lysosomal degradation pathway [13,14]. On the
other hand, increasing size in general reduces the ability of
the antibody fusion to penetrate tissue. The aspects of and
need for prolonging the half-life of popular small antibody
formats are reviewed in Kontermann 2009 [15].Besides extending the serum half-life of potential protein
therapeutics the Fc-region also confer other useful proper-
ties with regard to purification and immunochemistry. In
protein purification, the Fc-region allows binding to
protein A and protein G, hence supporting effective
one step purification by affinity chromatography [16,17].
With respect to the immunochemistry the presence of
the Fc-region facilitates detection using many common
secondary antibodies [18]. Other obvious tags for detec-
tion and purification such as His-tag and C-myc tag are
also present in our vector. One should nonetheless also
consider protein L for purification of those antibodies
holding a kappa light chain. We thus present a vector
construct, which allows for versatile strategies of purifi-
cation and immunochemistry.
The current method of choice for experimental scale ex-
pression of full-length antibody, and for formats including
the Fc-region, is transient expression in mammalian hosts,
such as Chinese hamster ovary cells (CHO) or Human
Embryonic Kidney cells (HEK) [19,20]. In such systems,
high expression levels can be obtained reaching triple-
digit mg/L levels. The drawbacks of mammalian cell ex-
pression systems are the need for dedicated labs and
equipment, the labour intensive handling, and the eco-
nomic considerations such as the price of reagents, cul-
ture medium, and labware [21].
Expression of recombinant proteins is one of the most
central disciplines in molecular biology and medical
research, and innovative systems with unique advantages
are thus constantly being explored [21]. Among emer-
ging systems is the one based on L. tarentolae, a proto-
zoan parasite infecting the gecko Tarentolae annularis.
The unicellular eukaryote L. tarentolae is an extensively
studied model for the disease leishmaniasis [22]. Their
unique transcriptional and translational machinery has
enabled the generation of novel expression systems
[23,24] based on the use of exogenous RNA polymerases
[25]. Properties like non-laborious handling, post-
translational modifications similar to those of mamma-
lian systems, episomal vector maintenance, and effective
secretion of recombinant proteins, are some of the
strengths of the L. tarentolae systems. Recent studies
aimed at addressing the importance of the signal peptide
cleavage site have shown that expression of scFv anti-
bodies (3.83 mg/L culture medium) can be obtained
using this system [26].
In order to validate the system for expression of Fc-
fused antibody fragments, we have created a vector
allowing expression and secretion of scFvs fused with
the Fc-region of rabbit IgG (rFc) using L. tarentolae T7-
TR (Jena Bioscience). The rFc is a convenient choice
when the fusion proteins are to be used in immuno-
chemical analysis of cells (ICC) and tissues (IHC) of
human or mice. This is essential to the research
Jørgensen et al. Microbial Cell Factories 2014, 13:9 Page 3 of 9
http://www.microbialcellfactories.com/content/13/1/9performed at laboratories, in which cells and tissues are
of human and mice origin, are used. Using the rFc re-
gion decreases the interaction, if any, between the en-
dogenous Fc-receptors and the rabbit Fc part. The use of
this rFc construct thus reduces the need to block the en-
dogenous Fc receptors of human and mouse tissue [27].
In summary, we here report a system based on
L. tarentolae T7-TR, for the production of rFc-fused
scFv antibodies. The resulting recombinant antibodies
are ideal for IHC or ICT on human or rodent material,
have a higher apparent affinity for multivalent antigens
due to avidity, and are compatible with convenient purifi-
cation methods. The expression host is characterised by
non-laborious handling requirements, eukaryotic post-
translational modification of expressed proteins with near-
mammalian N-glycan structures, and effective secretion of
recombinant protein to the culture medium [28].
Results and discussion
Construction of the vector pMJ-LEXSY-rFc for episomal
expression-secretion of scFv-rFc
The commercial episomal expression system based on
L. tarentolae T7-TR (Jena Bioscience) is appealing as the
target protein can be isolated directly from the culture
supernatant, enabling convenient one-step affinity purifi-
cation. In addition, expression in L. tarentolae facili-
tates post-translational modifications of proteins from
higher mammals [28]. However, the vector pLEXSY_IE-
blecherry4 does not allow for cloning via NcoI/NotI, a
routinely used restriction enzyme combination for anti-
body fragments [29], as this will remove the secretory
signal peptide and the polyhistidine stretch (His-tag). To
render NcoI/NotI cloning possible we replaced the exist-
ing expression cassette with a cassette from a modified
version of the pF4SPImsapX1.4sat vector using BglII and
MluI (own unpublished work). The expression cassette
from this vector comprises an NcoI/NotI cloning site
downstream from the signal peptide of L. mexicana se-
creted acid phosphatase 1 (LMSAP1) and a C-terminal
His-tag for purification followed by a c-Myc-tag for de-
tection. Replacement of the expression cassette was done
without changing the untranslated regions of the parent
vector; pLEXSY_IE-blecherry4. The new vector was
named pMJ-LEXSY. Moreover, for production of Fc-
fusion antibodies, we integrated the rabbit IgG Fc-
encoding region (hinge region and CH2-CH3) into the
pMJ-LEXSY vector whereby the pMJ-LEXSY-rFc vector
was generated (Figure 1). The rFc-encoding region was
inserted into the NotI site. The insert was prepared using
sticky PCR at one end of the insert, resulting in deletion
of the plus strand 3′ NotI site proximal to the tags upon
insertion of the rFc-encoding sequence [30]. Thus the
unique NotI restriction site was retained, allowing NcoI/
NotI insertion of antibody fragments.Expression and purification
Expressions (80–100 mL in 250 mL flasks) of the two
scFv-rFc constructs were carried out for 68-73 hours to
explore the level of expression at small-scale. In
addition, we explored the capacity of the expression sys-
tem to produce classical scFvs using the vector pMJ-
LEXSY. Three different scFvs, A10, LOB7, and Y4A
were expressed together with A10-rFc and LOB7-rFc
in L. tarentolae T7-TR (Figure 2). The antibody A10 is
an scFv derived from the Tomlinson I library [31]. It
binds to murine laminin from Engelbreth-Holm-Swarm
tumour cells. The antibody LOB7 in an scFv derived
from the Tomlinson J library [31]. This antibody binds
to human vimentin. The Y4A antibody is an scFv with
lambda light chain derived from the YAMO library [32].
This antibody recognises C5a anaphylatoxin. These
antibodies were chosen as model antibody fragments,
as we had significant experience in expressing them as
scFvs in E. coli.
Expression and subsequent purification by affinity
chromatography established that recombinant antibody
fragments could be obtained from all supernatants
(Figure 2). Purifications were carried out using Protein
A chromatography for the rFc constructs and Ni-NTA
Protein Purification for the scFvs. The expression levels
observed for the various clones ranged from 0.3 mg/L to
1 mg/L for the scFvs and from 0.6 mg/L to 2.95 mg/L
for the rFc-scFvs. Recently, Jäger et al. have shown that
yields up to 600 mg/mL of scFv-Fc fusion proteins can
be obtained by optimised transient expression in HEK
293 cells [19]. Although the yields in our work is signifi-
cantly lower, we still consider expression in L. tarentolae
beneficial due to the few requirements of implementing
this system into the laboratory and the non-laborious
handling of L. tarentolae.
When the purified proteins were analysed by SDS-
PAGE two bands were detected. This was also confirmed
by the western blot analysis (Figure 2) in which the
LOB7-rFc was detected with an HRP conjugated anti-
rabbit antibody. Additionally, the western blot analysis
could also confirm that the rFc-conjugated antibody as-
sembles into a bivalent structure in non-reducing con-
ditions. The same trend was seen for the A10-rFc
antibody (Additional file 1). The apparent heterogeneity
of size can be difficult to see for the non-reduced band
in the western blot. This is due to the fact that the
size difference of the two bands is relatively smaller to
the total mass of the assembled bivalent antibody,
hence giving a lower separation. This apparent hetero-
geneity of size was seen for all constructs; scFvs
(28 kDa) and scfv-rFcs (55 kDa) (Figure 2). To investi-
gate this issue we utilised that the pMJ-LEXSY-rFc vec-
tor (Figure 1) enables the removal of the His-tag and
the c-Myc-tag by TEV protease digestion. By removing
Figure 1 Description of vector pMJ-LEXSY-rFc. Top: DNA and protein sequence of cloning site and tag region of pMJ-LEXSY-rFc. Bottom:
Vectormap of pMJ-LEXSY-rFc. The T7/Tet region (blue) designates the T7 promoter under control of a Tet operator. LMSAP (black) is the secretory
leader-peptide of Secreted Acid Phosphatase 1 found in Leishmania Mexicana. The scFv A10 (red) is inserted via NcoI and NotI. The Fc-encoding
region of rabbit IgG (turquoise) including the IgG linker (green) is placed just downstream of NotI followed by a Tev restriction site (black), a
His-tag (yellow), and a c-Myc-tag (pink) encoding region. The bleomycin resistance gene is fused with a cherry gene, hence designated BleCherry.
This combination allows for selection of recombinants with bleomycin and subsequent screening of the best expressing clones by monitoring
the cherry fluorescence. The PciI restriction site is used for linearization and is placed in a telomere region (LTE + RTE), which upon transformation
stabilises the linear episome. Finally, the vector holds a tandem T7 transcription terminator (2xT7), a bacterial origin of replication (PBR322 ori),
and the Bla ampicillin resistance marker.
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to assess whether the source of size heterogeneity was
placed in the tag-region. SDS-PAGE analysis of LOB7-
rFc digested with TEV Protease showed that one band
appeared on the gel as opposed to two bands from
non-digested sample, confirming that the apparent het-
erogeneity of size was due to unpredicted modifications
of the tag-region (Additional file 2: Figure S1). Further-
more, western blot analysis and mass spectrometry on
the Y4A-scFv strongly suggest that the heterogeneity of
size emerges from a truncation of the c-Myc tag in
the lower molecular-weight protein (Additional file 2:
Figure S2-S4). The truncation of the c-Myc tag has
however no obvious influence on the intended applica-
tion of the scFv-rFcs in IHC and ICC using secondary
antibodies targeting the rFc-region.Functionality
To assess the binding activity of the scFv-rFcs, ELISAs
were performed (Figure 3) with A10-rFc and LOB7-rFc
against their respective antigens (mouse laminin and
human vimentin). The antigens were coated on ELISA
plates, targeted by the scFv-rFcs, and detected using
polyclonal swine anti-rabbit immunoglobulin HRP.
The rFc-constructs show specific binding to their cog-
nate antigens. Furthermore, the scFv-rFcs were detec-
table using HRP-conjugated anti-rabbit immunoglobulin.
The detection with the secondary antibody shows that
the rFc-regions were functionally intact, in line with the
fact that the antibodies can be purified using protein A
affinity chromatography [33]. On this basis we conclude
that our system is suitable for the production of rFc-
fused antibody fragments with uncompromised folding.
Figure 2 Antibodies expressed and purified from T7-TR.
Coomasie from the left: Molecular weight marker (SeeBlue plus2;
Invitrogen), A10 scFv, LOB7 scFv, Y4A scFv, A10 scFv-rFc, and LOB7
scFv-rFc. Western blot from the left: LOB7-rFc reduced (r), and
LOB7-rFc non-reduced (n-r). All antibodies seen in the Coomasie
stain were separated on SDS in reducing conditions.
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duction of antibodies intended for immunochemistry,
LOB7-rFc was used for immunocytochemical staining of
fixed and permeabilised human adult skin fibroblasts
(ASF-2) [34]. A commercial mouse monoclonal antibody
(V9) directed against vimentin was included as a bench-
mark for detection fidelity (Figure 4).
Both antibodies target vimentin, a cytoplasmic inter-
mediate filament. As can be seen, LOB7-rFc and com-
mercial V9 antibody produces similar labelling patterns
when binding to vimentin.
Conclusions
Antibody fragments fused to the Fc-region of IgG have
previously been produced in several organisms [35-39], but
to our knowledge this is the first time such constructs have
been expressed in L. tarentolae. The L.tarentolae system
offers a system capable of making N-glycosylations and
O-glycosylations. Breitling et al. reported the production of
biological active biantennary homogenously N-glycosylated
hEPO in L. tarentolae [23]. The N-glycosylations per-
formed in L. tarentolae are of higher mammal resemblance
than those performed in yeast and insect cells. Moreover,
studies by Klatt et al. [40] have shown that ssAlpha
expressed in L. tarentolae are O-glycosylated at the samesites as in mammal cells and furthermore displayed an in-
creased resistance to degradation compared to ssAplpha
expressed in E. coli [40].
At the same time L. tarentolae expression cultures can
be handled under standard laboratory conditions, similar
to the conditions used for propagation of E. coli cultures.
For the production of antibody fragments resulting from
high throughput screening, the system we describe here
presents substantial benefits: Firstly, the system can pro-
vide a rescue avenue for antibody fragments that express
poorly in E. coli. Secondly, the system can provide re-
combinant antibodies in a bivalent format incorporating
a native Fc-region; a format ideally suited for use in im-
munostaining of cells and tissues.
Methods and material
Vector construction
All restriction enzymes, polymerases, and chemicals
used for cloning and PCR were purchased from Fermen-
tas (Thermo Scientific Molecular Biology). Oligonucleo-
tides used are listed in Table 1, and were purchased
from Sigma Aldrich. To make the pLEXSY_IE-ble-
cherry4 applicable for NcoI/NotI cloning of scFv anti-
bodies for secretion an expression cassette from the
vector pF4NAF was cloned into pLEXSY_IE-blecherry4
via BglI and MluI. The pF4NAF expression cassette had
been constructed previously using components of two
vectors; pIT2 [31] and pF4SPImsapX1.4sat (Jena Bio-
science; Cat. No. EGE-211). In this previous work, the
vector pF4SPImsapX1.4sat (an early version of pLEXSY-
sat2, Jena Bioscience; Cat. No. EGE-234) was modified
by deleting the NcoI with primer Z and primer X, by use
of PCR amplification of the region between BglII and
NotI. The PCR product, now deleted for NcoI, was sub-
sequently digested with BglII and NotI and re-inserted
into the pF4SPImsapX1.4sat. Next, the expression cas-
sette from the vector pIT2 was PCR amplified using pri-
mer A and primer B, followed by a digestion of the PCR
product with KasI (5′ digestion) and Bsp120I (3′ diges-
tion). Bsp120I produces overhangs compatible with NotI.
The PCR amplified expression cassette of pIT2 was then
inserted into pF4SPImsapX1.4sat via KasI and NotI
hereby creating the pF4NAF cassette. In the ligation of
the Bsp120I overhang to the NotI overhang the recogni-
tion sequence for both was destroyed. This cassette was
inserted into pLEXSY_IE-blecherry4 via BglI and MluI,
resulting in pMJ-LEXSY. The ligated DNA was used to
transform electrocompetent XL1-Blue, and the cells
were plated on TYE agar-plates containing 100 μg/mL
ampicillin (Sigma Aldrich). The plates were incubated
overnight at 30°C and colonies were picked for sequence
analysis. To construct the rFc-fusion vector pMJ-LEXSY-
rFc, the Fc encoding region of rabbit IgG (hinge region
and CH2-CH3) was amplified by two rounds of PCR
Figure 3 ELISA; specific binding of rFc fusion scFvs against their cognate antigens. To test if the scFv-rFc antibodies bind their cognate antigens
ELISA plates were coated with laminin (A10 scFv-rFc) and vimentin (LOB7 scFv-rFc). For both antibody constructs specific binding is seen.
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plate [18]. The two PCR amplifications were performed
applying primer pairs c/d and c/e. respectively. The rFc-
encoding region was prepared for cloning using sticky
end PCR as earlier described [30] and inserted into the
NotI site of pMJ-LEXSY. The Ligations were electro-
porated into XL1-Blue and plated on agar-plates holding
100 μg/mL ampicillin. Colony PCR was used to identify
positive clones and correct orientation of DNA inserts
were verified by sequencing (Eurofins MWG).
Cultivation and transformation
XL1-Blue
Before transformation, XL1-Blue cells were made elec-
trocompetent roughly as described for Pseudomonas
Putida in [41], but without adding sucrose to the storage
medium. Batches of competent E. coli were frozen in
liquid nitrogen and stored at −80°C. ElectroporationFigure 4 Using LOB7-rFc and V9 antibody for Immunocytochemistry.
(D, E) and detected with Goat-anti-Rabbit Alexa Fluor 488 (green) and Goa
(C, F) were done leaving out primary antibodies. The cell nuclei were stain
intermediate filament. Both give excellent staining. (Scale bar, 20 μm).was carried out in 2 mm pre-chilled cuvettes holding
20-30 ng of vector and 50 μL cells. The cells were pulsed
at 2500 V using an Electroporator 2510 (Eppendorf) and
plated on TYE agar-plates with 100 μg/mL ampicillin. For
plasmid propagation, XL1-Blue were grown at 30°C and
200 rpm in baffled Erlenmeyer flasks containing PDM
medium [42] with 100 μg/mL ampicillin.
Leishmania tarentolae T7-TR
Manipulation of T7-TR was performed in accordance with
Jena Bioscience protocols (Cat. No. EGE-1420blecherry).
In brief, T7-TR were cultivated and maintained in tissue
culture flasks (TC25) as static suspensions at 26°C. The
flasks were placed upright, in the dark, and with the venti-
lating cap in the open position. Non-transformed Leish-
mania tarentolae T7-TR were grown in 10–15 mL LEXSY
BHI medium per flask. The cells were passaged twice
weekly in ratios of 1:50 or 1:20 on Mondays and FridaysThe cell line ASF-2 were stained with LOB7 scFv-rFc (A, B) and V9
t-anti-Mouse Alexa Fluor 546 (red) respectively. Negative controls
ed with DAPI (blue). Both LOB7 and V9 detect vimentin, a cytoplasmic
Table 1 Primers used in this study
Primer z 5′ GCAGCCAGATCTAATATGGCTTCTAGGCTCGTCCG 3′
Primer x 5′ AGGAGGGCGGCCGCTTA ′3
Primer A 5′ CGCGTGGGCGCCATGGCCGAGGTGCAG 3′
Primer B 5′ CTGCAAGGGCCCCTATGCGGCCCCATTCAGATC 3′
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in 50 μL of water was incubated with 350 μL densely sus-
pended Leishmania tarentolae T7-TR (OD600 > 2). Elec-
troporation was carried out in pre-chilled 2 mm cuvettes.
Cells were pulsed in a GENEPULSER Xcell (BIORAD)
at 450 V and 450 μF, obtaining a pulse time in ranges of
5-6.5 ms. The cells were kept on ice for exactly 10 minutes
after electroporation. Immediately hereafter the cells were
transferred to a T25 flask and grown for 20 hours in
10 mL of non-selective LEXSY BHI medium. Cells were
subsequently gently dispensed onto selective LEXSY BHI
agar plates and grown for 10 days at 26°C in the dark. The
plates for clonal selection contained 100 μg/mL Zeocin
(Invitrogen). All colonies visible after 10 days were picked
from the plates, and each clone was then cultivated in se-
lective LEXSY BHI medium for one day in a single well of
a 24-well plate. This cultivation was performed in 1 mL
selective LEXSY BHI medium with 100 μg/mL zeocin
(Invitrogen). The cell density and condition was assessed
in the microscope and clones with low growth were culti-
vated for further 1–2 days before they were transferred to
a larger volume. Clones exhibiting acceptable motility, cell
shape, and growth were transferred to 5 mL selective
LEXSY BHI medium and grown to OD 1.4. Assessment of
expression levels for each clone was conducted in 96-well
plates by inducing the expression with 100 μg/mL tetra-
cycline. The cherry fluorescence of each clone was mea-
sured at 584 nm excitation/612 nm emission in a
POLARstar OPTIMA fluorimeter (BMG Labtech).
Expression and purification
Clones displaying the highest level of cherry fluorescence
were chosen for the further work. Expression was car-
ried out in 100 mL LEXSY BHI medium containing
100 μg/mL tetracycline (Sigma Aldrich) and 100 μg/mL
Zeocin (Invitrogen). Transformed L. tarentolae T7-TR
(OD600 1.4-2) were innoculated 1:10 into 100 mL cul-
tures. The culturing was performed in the dark at 26°C
for 72 hours in 250 mL baffled Erlenmeyer flasks with
agitation (120 rpm). The cultures were centrifuged at
2700 × g for 30 min to precipitate cells and the proteins
present in the supernatant precipitated by using 30% m/vammonium sulphate. The precipitated proteins were then
pelleted at 5250 × g for 45 min and re-suspended in 0.5 ×
PBS. Finally, affinity purification using a Protein A HP
spinTrap column (GE healthcare) was used for recovery of
the scFv-rFc antibodies. The scFv antibodies were purified
using a Maxwell 16 instrument in combination with a
Maxwell 16 Polyhistidine Protein Purification Kit (Pro-
mega). Protein concentrations were estimated by absorp-
tion at 280 nm using a NanoDrop 1000 instrument
(Thermo Scientific) and applying the protein specific mo-
lecular weights and molar extinction coefficients. A re-
peated and up-scaled expression of LOB7-rFc was
performed as described above, but this time as 5 times
80 mL cultures incubated for 72 hours in 250 mL baffled
Erlenmeyer flasks. Supernatants from all cultures were
pooled before the proteins were precipitated. The ammo-
nium sulphate precipitated proteins were then resus-
pended in 20 mM sodium phosphate and purified by
using a 1 mL HiTrap Protein A HP column. Protein A




Maxisorp 96-well flat bottom plates (Nunc) were coated
with 30 μL of the relevant antigens at 20 μg/mL (in 2%
BSA-PBS) for both vimentin and laminin. The protein
was adsorbed to the plates during storage at 4°C over-
night. Each well was washed with three times 200 μL
PBS using a multi-channel pipette, before the plates
were blocked with 300 μL 2% BSA in PBS (BSA-PBS) for
1 hour at room temperature under gentle agitation. The
washing step was then repeated, followed by the addition
of serial dilutions of scFv-rFcs in 100 μL 2% BSA-PBS.
The antibodies were incubated in the antigen-coated
wells for 1.5 hour at room temperature, and subse-
quently the plates were washed three times with PBS,
each time for 5 min. Detection of bound scFv-rFcs was
performed by incubating the plates with polyclonal
swine anti-Rabbit Immunoglobulins (Dako) in a 1:2000
dilution in 2% BSA-PBS for 1 hour. Finally, the plates
were washed three times with PBS, each time for 5
minutes. The amount of bound antibody was visualised
by the addition of 80 uL TMB single solution (Sigma
Aldrich), and the colour reaction was terminated after
7 minutes by the addition of 50 μL 1 M H2SO4 to each
well. Absorbance was measured at 450 nm and corrected
for at 655 nm. The absorbance was conducted in a mi-
croplate reader; Model 550 (Bio Rad).
Eukaryotic cell handling and Immunocytochemistry
ASF-2 cells were grown in DMEM (Lonza) with 10%
fetal bovine serum (Thermo Scientific), 100 U/mL peni-
cillin and streptomycin (Lonza) at 37°C, 5% CO2 and
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http://www.microbialcellfactories.com/content/13/1/995% humidity. ASF-2 cells of passage 10 were detached
from a tissue culture flask by trypsination with Trypsin
EDTA (Lonza) and spun down at 600 g for 6 minutes.
Cells were then resuspended in growth medium and
15.000 cells/well were seeded out in an ibiTreat μ-Slide
VI 0.4 (Ibidi) and grown overnight. The next day the
cells were rinsed with PBS, fixed in 4% PFA for 15 min.,
permeabilised with 0.025% Triton X100 (Sigma-Aldrich)
for 10 min. and blocked with 2% BSA in PBS (BSA-PBS) for
1 hour at room temperature. The cells were incubated with
5 μg of purified LOB7 in 2% BSA-PBS or 100 μl of a 1:100
dilution of V9 antibody in 2% BSA-PBS (Sigma Aldrich) pr.
well for 1 hour at room temperature. Visualisation of LOB7
was accomplished by incubation with a 1:100 dilution of
Goat-anti-Rabbit Alexa Fluor 488 (Invitrogen, USA). V9
was visualised by a 1:100 dilution of Goat-anti-Mouse Alexa
Fluor 546 (Invitrogen). Cell nuclei were stained with Vecta-
shield Mounting Medium with DAPI (Vector Labs).
Fluorescent images were obtained with a Leica DMI3000
B inverted microscope (Leica Microsystems).
Additional files
Additional file 1: SDS PAGE showing reduced and non-reduced rFc
constructs.
Additional file 2: Figure S1. SDS PAGE analysis of TEV Protease
digested LOB7-rFc. To assess if the heterogeneity correlated to
modifications of the C-terminal tag region, we digested LOB7-rFc with
TEV Protease. (1) Non-digested LOB7-rFc showing two bands (2) LOB7-rFc
digested with TEV Protease showing one band. Therefore, the size
heterogeneity resides in the C-terminal tag-region. Figure S2 - Western
blot analysis of Y4A-scFv. (A) Western blot analysis of 0.018 μg and
0.09 μg Y4A-scFv using an anti-His antibody. Two bands appeared after
exposure for 1 min and 10 sec, respectively. (B) Western blot analysis on
0.45 μg Y4A-scFv using an anti c-Myc antibody. The films were exposed
1 min and 10 sec, displaying only one band. (C) Coomasie stain of the
Y4A-scFv. Figure S3 - Verification of degradation of c-Myc-tag by
mass spectrometry (MS). The bands detected by SDS-PAGE were
subjected to in-gel digestion using Lys-C and the peptides were
subsequently analysed by MALDI-TOF mass spectrometry. Ions in the
range m/z 1500–2500 are shown. An ion of m/z 2221.28 was detected in
the upper band whereas an ion of m/z 1693.91 in the lower band. The
mass difference (~500 Da.) correlates with the mass difference observed
by SDS-PAGE. Figure S4 - MSMS analysis of heterogeneous antibody.
To evaluate the identity of the ions detected, we subjected them to
MSMS analysis. (A) The analysis of the ion detected in the upper band
produced fragment ions corresponding to the peptide represented by
Leu239-Lys258 encompassing the His-tag and three amino acid residues
of the c-myc tag. The C-terminal Lys258 indicates that this peptide is generated
by Lys-C cleavage. (B) The ion of m/z 1693.91 was found to represent
Leu239-Gly253. It is thus likely that the C-terminal Gly253 represents the
C-terminus of the mature protein excised from the gel (lower band).
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